Expression and immunogenicity of a tumor‐associated antigen, 90K/Mac‐2 binding protein, in lung carcinoma
Authors:
- Keiichi KontaniKKKeiichi Kontani
- Jun HanaokaJHJun Hanaoka
- Tokuhiro ChanoTCTokuhiro Chano
- Koji TeramotoKTKoji Teramoto
- Noriaki TezukaNTNoriaki Tezuka
- Satoru SawaiSSSatoru Sawai
- Shozo FujinoSFShozo Fujino
- Tatsuhiro YoshikiTYTatsuhiro Yoshiki
- Hidetoshi OkabeHOHidetoshi Okabe
- Iwao OhkuboIOIwao Ohkubo
Open Access
Abstract
BACKGROUND The authors attempted to obtain shared proteins among lung carcinoma cells by column chromatographies. A glycoprotein with approximately 500 kDa isolated from QG56 cells showed an identical amino acid sequence to 90K/Mac‐2 binding protein (M2BP). This protein has been reported to be highly expressed and to modulate the expression of surface molecules involved in immune responses on cultured cancer cells. Therefore, it would be beneficial for M2BP to be targeted in cancer immunotherapy. METHODS The authors analyzed the expression of M2BP in lung carcinoma cells and M2BP's immunogenicity as a tumor antigen. Eight cultured lung carcinoma cell lines and 28 tumor tissues from patients with lung carcinoma were examined for the expression of M2BP mRNA and protein. Sera from cancer patients (n = 23) and healthy donors (n = 19) were studied for their reactivity to M2BP peptides by enzyme–linked immunosorbent assay. RESULTS Seven of the 8 (87.5%) lung carcinoma cell lines and 17 of the 28 (60.7%) tumor tissues expressed high levels of M2BP mRNA. Most of the M2BP mRNA‐positive cancer cell lines and tumors also showed M2BP protein expression. The serum levels of antibodies to M2BP were elevated in 30.4% of the patients. In addition, M2BP‐specific immunoglobulin G was observed in all patients with anti‐M2BP antibodies. CONCLUSIONS M2BP is highly expressed in lung carcinoma cells and is sufficiently immunogenic to elicit specific immunity to this molecule in patients with lung carcinoma. M2BP is expected to be useful as a tumor marker and a target antigen in cancer immunotherapy. Cancer 2002;95:1954–62. © 2002 American Cancer Society. DOI 10.1002/cncr.10899Keywords
This publication has 37 references indexed in Scilit:
- Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to α-interferon therapy in chronic HCV hepatitis patientsJournal of Hepatology, 1996
- The Immune Stimulatory Protein 90K Increases Major Histocompatibility Complex Class I Expression in a Human Breast Cancer Cell LineBiochemical and Biophysical Research Communications, 1996
- Human tumor antigens recognized by T lymphocytes.Journal of Experimental Medicine, 1996
- A Tumor-Derived Protein which Provides T-Cell Costimulation through Accessory Cell ActivationJournal of Immunotherapy, 1995
- Expression of tumor‐associated 90k‐antigen in human breast cancer: No correlation with prognosis and response to first‐line therapy with tamoxifenInternational Journal of Cancer, 1995
- Purification and characterization of a 90 kDa protein released from human tumors and tumor cell linesFEBS Letters, 1993
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991
- Lipoprotein 90K in Human Immunodeficiency Virus-Infected Patients: A Further Serologic Marker of ProgressionThe Journal of Infectious Diseases, 1991
- Unusually High Level of a Tumor-Associated Antigen in the Serum of Human Immunodeficiency Virus-Seropositive IndividualsThe Journal of Infectious Diseases, 1991
- Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patientsBreast Cancer Research and Treatment, 1988